14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $12.37 $15.43 Wednesday, 1st May 2024 URGN stock ended at $14.40. This is 4.20% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 5.47% from a day low at $13.89 to a day high of $14.65.
90 days $12.37 $19.87
52 weeks $8.69 $24.13

Historical UroGen Pharma Ltd prices

Date Open High Low Close Volume
May 03, 2023 $13.06 $13.67 $12.29 $12.80 340 508
May 02, 2023 $14.24 $14.76 $12.90 $13.06 419 757
May 01, 2023 $11.59 $16.11 $11.26 $14.29 1 825 585
Apr 28, 2023 $12.57 $12.70 $10.28 $11.59 280 143
Apr 27, 2023 $12.41 $12.94 $12.08 $12.46 219 999
Apr 26, 2023 $11.62 $12.45 $11.35 $12.25 177 584
Apr 25, 2023 $11.50 $12.25 $11.30 $11.61 644 573
Apr 24, 2023 $9.89 $11.58 $9.69 $11.55 301 225
Apr 21, 2023 $9.75 $10.35 $9.51 $10.04 163 446
Apr 20, 2023 $10.14 $10.32 $9.52 $9.66 210 158
Apr 19, 2023 $9.49 $10.30 $9.34 $10.20 219 373
Apr 18, 2023 $9.79 $9.79 $9.42 $9.53 54 048
Apr 17, 2023 $9.75 $10.13 $9.41 $9.60 104 710
Apr 14, 2023 $9.90 $10.42 $9.43 $9.63 133 788
Apr 13, 2023 $9.09 $10.10 $9.04 $9.85 174 469
Apr 12, 2023 $9.39 $9.39 $8.90 $9.17 84 966
Apr 11, 2023 $9.48 $9.49 $9.01 $9.28 52 919
Apr 10, 2023 $8.79 $9.51 $8.57 $9.39 83 336
Apr 06, 2023 $8.80 $9.00 $8.60 $8.80 113 189
Apr 05, 2023 $9.00 $9.34 $8.68 $8.75 52 305
Apr 04, 2023 $9.75 $9.81 $8.93 $8.96 124 983
Apr 03, 2023 $9.20 $9.98 $9.05 $9.75 206 602
Mar 31, 2023 $8.49 $9.78 $8.42 $9.24 262 868
Mar 30, 2023 $8.77 $8.80 $8.26 $8.38 139 157
Mar 29, 2023 $8.09 $9.66 $8.00 $8.83 342 810
Click to get the best stock tips daily for free!

About UroGen Pharma Ltd

UroGen Pharma Ltd UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms... URGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT